These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 20859991)

  • 41. New role for nuclear hormone receptors and coactivators in regulation of BRCA1-mediated DNA repair in breast cancer cell lines.
    Crowe DL; Lee MK
    Breast Cancer Res; 2006; 8(1):R1. PubMed ID: 16417649
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Estrogen induces androgen-repressed SOX4 expression to promote progression of prostate cancer cells.
    Yang M; Wang J; Wang L; Shen C; Su B; Qi M; Hu J; Gao W; Tan W; Han B
    Prostate; 2015 Sep; 75(13):1363-75. PubMed ID: 26015225
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The steroid receptor co-activator-1 (SRC-1) potentiates TGF-beta/Smad signaling: role of p300/CBP.
    Dennler S; Pendaries V; Tacheau C; Costas MA; Mauviel A; Verrecchia F
    Oncogene; 2005 Mar; 24(11):1936-45. PubMed ID: 15688032
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Inhibition of SULT2B1b expression alters effects of 3beta-hydroxysteroids on cell proliferation and steroid hormone receptor expression in human LNCaP prostate cancer cells.
    He D; Falany CN
    Prostate; 2007 Sep; 67(12):1318-29. PubMed ID: 17626250
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The androgen receptor co-activator CBP is up-regulated following androgen withdrawal and is highly expressed in advanced prostate cancer.
    Comuzzi B; Nemes C; Schmidt S; Jasarevic Z; Lodde M; Pycha A; Bartsch G; Offner F; Culig Z; Hobisch A
    J Pathol; 2004 Oct; 204(2):159-66. PubMed ID: 15378487
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cooperation of the transcriptional coactivators CBP and p300 with Stat6.
    McDonald C; Reich NC
    J Interferon Cytokine Res; 1999 Jul; 19(7):711-22. PubMed ID: 10454341
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A CRISPR Interference of CBP and p300 Selectively Induced Synthetic Lethality in Bladder Cancer Cells
    Li J; Huang C; Xiong T; Zhuang C; Zhuang C; Li Y; Ye J; Gui Y
    Int J Biol Sci; 2019; 15(6):1276-1286. PubMed ID: 31223286
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Adenoviral E1A-associated protein p300 as a functional homologue of the transcriptional co-activator CBP.
    Lundblad JR; Kwok RP; Laurance ME; Harter ML; Goodman RH
    Nature; 1995 Mar; 374(6517):85-8. PubMed ID: 7870179
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Nuclear receptors have distinct affinities for coactivators: characterization by fluorescence resonance energy transfer.
    Zhou G; Cummings R; Li Y; Mitra S; Wilkinson HA; Elbrecht A; Hermes JD; Schaeffer JM; Smith RG; Moller DE
    Mol Endocrinol; 1998 Oct; 12(10):1594-604. PubMed ID: 9773982
    [TBL] [Abstract][Full Text] [Related]  

  • 50. HOXC8 inhibits androgen receptor signaling in human prostate cancer cells by inhibiting SRC-3 recruitment to direct androgen target genes.
    Axlund SD; Lambert JR; Nordeen SK
    Mol Cancer Res; 2010 Dec; 8(12):1643-55. PubMed ID: 21047772
    [TBL] [Abstract][Full Text] [Related]  

  • 51. CREB-binding protein and p300/CBP-associated factor are transcriptional coactivators of the p53 tumor suppressor protein.
    Scolnick DM; Chehab NH; Stavridi ES; Lien MC; Caruso L; Moran E; Berger SL; Halazonetis TD
    Cancer Res; 1997 Sep; 57(17):3693-6. PubMed ID: 9288775
    [TBL] [Abstract][Full Text] [Related]  

  • 52. FT-6876, a Potent and Selective Inhibitor of CBP/p300, is Active in Preclinical Models of Androgen Receptor-Positive Breast Cancer.
    Caligiuri M; Williams GL; Castro J; Battalagine L; Wilker E; Yao L; Schiller S; Toms A; Li P; Pardo E; Graves B; Azofeifa J; Chicas A; Herbertz T; Lai M; Basken J; Wood KW; Xu Q; Guichard SM
    Target Oncol; 2023 Mar; 18(2):269-285. PubMed ID: 36826464
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The prognostic capacities of CBP and p300 in locally advanced rectal cancer.
    Rühlmann F; Windhof-Jaidhauser IM; Menze C; Beißbarth T; Bohnenberger H; Ghadimi M; Dango S
    World J Surg Oncol; 2019 Dec; 17(1):224. PubMed ID: 31856851
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Androgen receptor co-activators in the regulation of cellular events in prostate cancer.
    Culig Z; Santer FR
    World J Urol; 2012 Jun; 30(3):297-302. PubMed ID: 22105110
    [TBL] [Abstract][Full Text] [Related]  

  • 55. CBP/p300 Degrader: A Promising Therapeutic Strategy for Treatment of Prostate Cancer and Beyond.
    Hu J; Xu Y
    J Med Chem; 2024 Apr; 67(7):5272-5274. PubMed ID: 38517344
    [TBL] [Abstract][Full Text] [Related]  

  • 56. AR coactivators, CBP/p300, are critical mediators of DNA repair in prostate cancer.
    Sardar S; McNair CM; Ravindranath L; Chand SN; Yuan W; Bogdan D; Welti J; Sharp A; Ryan NK; Schiewer MJ; DeArment EG; Janas T; Su XA; Butler LM; de Bono JS; Frese K; Brooks N; Pegg N; Knudsen KE; Shafi AA
    bioRxiv; 2024 May; ():. PubMed ID: 38766099
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Modulating the masters: chemical tools to dissect CBP and p300 function.
    Breen ME; Mapp AK
    Curr Opin Chem Biol; 2018 Aug; 45():195-203. PubMed ID: 30025258
    [TBL] [Abstract][Full Text] [Related]  

  • 58. AR coactivators, CBP/p300, are critical mediators of DNA repair in prostate cancer.
    Sardar S; McNair CM; Ravindranath L; Chand SN; Yuan W; Bogdan D; Welti J; Sharp A; Ryan NK; Knudsen LA; Schiewer MJ; DeArment EG; Janas T; Su XA; Butler LM; de Bono JS; Frese K; Brooks N; Pegg N; Knudsen KE; Shafi AA
    Oncogene; 2024 Oct; 43(43):3197-3213. PubMed ID: 39266679
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pharmacological Inhibition of CBP/p300 Blocks Estrogen Receptor Alpha (ERα) Function through Suppressing Enhancer H3K27 Acetylation in Luminal Breast Cancer.
    Waddell A; Mahmud I; Ding H; Huo Z; Liao D
    Cancers (Basel); 2021 Jun; 13(11):. PubMed ID: 34199844
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Loss of p300 accelerates MDS-associated leukemogenesis.
    Cheng G; Liu F; Asai T; Lai F; Man N; Xu H; Chen S; Greenblatt S; Hamard PJ; Ando K; Chen X; Wang L; Martinez C; Tadi M; Wang L; Xu M; Yang FC; Shiekhattar R; Nimer SD
    Leukemia; 2017 Jun; 31(6):1382-1390. PubMed ID: 27881875
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.